HT
SGMO

Headlands Technologies’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Headlands Technologies’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-5
Closed -$5 – 1483
2024
Q4 		$5 Buy
+5
New +$9 ﹤0.01% 1160
2023
Q3 		– Sell
-17,944
Closed -$23.3K – 1174
2023
Q2 		$23.3K Buy
+17,944
New +$24.5K 0.01% 547

Other funds holding SGMO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Headlands Technologies's SGMO Position: Q1 2025 in Review

Headlands Technologies sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q1 2025, closing a stake of 5 shares — an estimated $5 sold.

Headlands Technologies first reported a position in SGMO in Q2 2023 and held it in 2 quarters. The position peaked at $23.3K in Q2 2023. 122 funds tracked by Wall St. Rank hold SGMO as of Q1 2025.

  • Headlands Technologies reported no remaining SANGAMO THERAPEUTICS INC position as of Q1 2025 after selling out during the quarter.
  • Headlands Technologies sold 5 SANGAMO THERAPEUTICS INC shares in Q1 2025, an estimated $5.
  • Headlands Technologies first reported a position in SANGAMO THERAPEUTICS INC in Q2 2023 and held it in 2 quarters.
  • Headlands Technologies's SANGAMO THERAPEUTICS INC position peaked at $23.3K in Q2 2023.
  • 122 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q1 2025.

Based on Headlands Technologies's 13F filing for Q1 2025, filed 9 May 2025.